This Sunday I had a very enjoyable experience giving a guest lecture at the University of Southern California’s Healthcare Decision Analysis program (specifically class HCDA 520). The topic of the class was “Health Economics & Outcomes Methodology” and my lecture was on “Novel approaches to quantifying value”. Thank you to Professor Daniel Tomaszewski for inviting …
That is the title of a recent commentary published in the Journal of Clinical Pathways with my colleague David Gruber. New digital technologies have the potential to greatly improve our healthcare system on multiple fronts. Telemedicine allowed many patients to communicate with their doctors during the COVID-19 pandemic; during the height of the pandemic, 30% of …
That is the title of a recent paper published in the Journal of Medical Economics with Syvart Dennan, Oliver Diaz, Kelly Birch, Jennifer Cai, Jennifer Sung, and Paula Machado. The subtitle is: A case study of increased graft survival on the US kidney transplant waitlist. The abstract is below: Aim: To quantify the wider impacts …
Quantifying spillover benefits in value assessment Read More »
That is the finding from a white paper from the Schizophrenia and Psychosis Action Alliance titled “Societal Costs of Schizophrenia & Related Disorders“. I am a co-author on the paper. Below is a summary of the findings: …the societal costs of schizophrenia were estimated to be $281.6 billion in 2020…Direct costs for individuals living with …
Total Cost of Schizophrenia in the US was nearly $300 billion in 2020 Read More »
I will be on a panel tomorrow for the Wall Street Journal‘s Global Food Forum. My panel will include and Hakim Bouzamondo (Divisional VP, Global Research and Development, Nutrition at Abbott) and Dr. Leah Gramlich, (Gastroenterologist and Physician Nutrition Specialist at the Royal Alexandra Hospital in Alberta Canada) as well as myself. This discussion will …
In an article in Health Affairs, Rick van der Vegte and I argue that in four specific cases, the answer is yes. …the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) developed a “value flower,” which aims to more comprehensively capture all elements of value relevant for measuring the value of a new health technology. …
Should supply chain quality inform treatment value? Read More »
That is the title of a recent study I published with Michael Halasy in Mayo Clinic Proceedings. The subtitle is Establishing a Theoretical Model to Evaluate the Value of Second Opinion Visits. The abstract is below: In order to produce a mathematical model for better understanding of the benefits and utilization of second opinions and …
That is the title of a paper I just published at Value in Health with Suepattra G. May, Lauren M. Zhao, Katalin Bognar, Yong Yuan, John R. Penrod, and John A. Romley. The subtitle is A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer. The full abstract is below: Objectives: To compare …
This is the question I–along with co-authors Syvart Dennen, Priti Pednekar , Kelly Birch, Menaka Bhor, Julie Kanter , and Peter Neumann–aim to answer in our new paper in JMCP. The full title is: “For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports“. The abstract is below. BACKGROUND: U.S. …
For which diseases do broader value elements matter most? Read More »
I provide the answer to this question in a recent paper in Current Medical Research & Opinion with co-authors Howard Thom, Edna Keeney, Daisy Gaunt, Lauren Zhao, Menaka Bhor, Avery Rizio, Lanetta Bronté-Hall and Nirmish Shah. The abstract is below. AimSickle cell disease (SCD) is a lifelong blood disorder affecting approximately 100,000 individuals in the …
That is the title of my latest publication with co-authors Marlon Graf, Rifat Tuly, Christoph Glaetzer, Stacey Hickson, and Joey Mattingly. The subtitle is “How to Ensure Continued COVID-19 Vaccine Discovery and Expedite Access“. The abstract is below. The coronavirus disease 2019 (COVID-19) pandemic has resulted in a catastrophic burden in both health and economic …
This is the title of a paper published today with co-authors Suepattra May, Caroline Huber, Meaghan Roach, Wade Aubry, Darius Lakdawalla, John Kane, and Felicia Forma. The subtitle is “Qualitative Case Study of Glucose Monitoring Technology“. The abstract is below. Background: Evaluation of patients with serious mental illness (SMI) relies largely on patient or caregiver …
Adoption of Digital Health Technologies in the Practice of Behavioral Health Read More »
That is the topic of a commentary I wrote with co-authors Joanna MacEwan and Farzad Ali, titled “Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?” An excerpt is below: Cancer mortality rates have fallen significantly over the last 20 years. Between 2000 and 2010, overall age-adjusted …
Tomorrow, Monday, November 16 at 15:00 CET (9:00 EST/6:00 PST), I will be on an ISPOR Europe Panel titled “Will COVID-19 Accelerate the Adoption of Digital Health Technologies? Perspectives on Evaluating Digital Health Technologies during Global Disease Outbreaks“. The session will be moderated by Kristian Kidholm, PhD of the University of Southern Denmark, and my …
That is the finding from a recent paper by myself and co-authors Joanna MacEwan, Syvart Dennen, Rebecca Kee, Farzad Ali, and Katharine Batt. An excerpt from the paper is below: Between 2000 and 2016, deaths per 100,000 population across the 15 most common tumor types declined by 24%. Additionally, 10.2 new indications were approved per …
That is the title of an article in AJMC co-authored with Meena Venkatachalam. An excerpt is below: While decision-makers traditionally have ignored the issue of inequality, academic researchers have already developed tools to quantify a treatment’s value from reductions in inequality. Two common methods for doing so are distributional cost effectiveness analysis (DCEA) and multiple-criteria …
Steps Health Professionals Can Take to Reduce Inequality in Health Outcomes Read More »
I’m very excited to announce that the study: “Alternative payment models and innovation: A case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure” has been published in the Journal of Medical Economics last week. Co-authors on the paper are Elmar R. Aliyev, Michelle Brauer, Siyeon Park and Xian …
That is the title of my recent blog post in Health Affairs with my co-author Meena Venkatachalam. The subtitle is “Expanding Value Assessment To Incorporate Health Inequality“. An excerpt is below: The brutal murder of George Floyd has brought renewed attention to systemic inequality that African Americans and other minorities face in the United States …
Creating Incentives To Narrow The Gap In Health Outcomes Read More »
English
Afrikaans
Shqip
አማርኛ
العربية
Հայերեն
Azərbaycan dili
Euskara
Беларуская мова
বাংলা
Bosanski
Български
Català
Cebuano
Chichewa
简体中文
繁體中文
Corsu
Hrvatski
Čeština
Dansk
Nederlands
Esperanto
Eesti
Filipino
Suomi
Français
Frysk
Galego
ქართული
Deutsch
Ελληνικά
ગુજરાતી
Kreyol ayisyen
Harshen Hausa
Ōlelo Hawaiʻi
עִבְרִית
हिन्दी
Hmong
Magyar
Íslenska
Igbo
Bahasa Indonesia
Gaelige
Italiano
日本語
Basa Jawa
ಕನ್ನಡ
Қазақ тілі
ភាសាខ្មែរ
한국어
كوردی
Кыргызча
ພາສາລາວ
Latin
Latviešu valoda
Lietuvių kalba
Lëtzebuergesch
Македонски јазик
Malagasy
Bahasa Melayu
മലയാളം
Maltese
Te Reo Māori
मराठी
Монгол
ဗမာစာ
नेपाली
Norsk bokmål
پښتو
فارسی
Polski
Português
ਪੰਜਾਬੀ
Română
Русский
Samoan
Gàidhlig
Српски језик
Sesotho
Shona
سنڌي
සිංහල
Slovenčina
Slovenščina
Afsoomaali
Español
Basa Sunda
Kiswahili
Svenska
Тоҷикӣ
தமிழ்
తెలుగు
ไทย
Türkçe
Українська
اردو
O‘zbekcha
Tiếng Việt
Cymraeg
isiXhosa
יידיש
Yorùbá
Zulu